Outcomes in SCS Trials Ali Rezai MD.

Slides:



Advertisements
Similar presentations
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Advertisements

Fundamentals of Clinical Trials
Standardized Scales.
Patient-reported Measures: KCCQ and CHF outcomes Aanand D. Naik, MD Houston Health Services Research and Development Center of Excellence.
Methods used to assess and report pain-related endpoints in NDA Ethan Basch, MD, MSc Center for Drug Evaluation and Research.
Dose-Toxicity Study of Oral Prednisone in Ocular Myasthenia Michael Benatar, Mike McDermott, Gil Wolfe and Don Sanders.
Successful Treatment of Low Back Pain with a Novel Neuromodulation Device Iris Smet, MD 1 Jean-Pierre Van Buyten, MD 1 Adnan Al-Kaisy MB ChB FRCA 2 1 AZ.
INCLUSION/EXCLUSION CRITERIA 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion.
Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.
NEUROPATHIC PAIN – OPTIMIZING PATIENT OUTCOME WITH COMBINATION THERAPY.
The Relation of Negative Life Events to Symptoms and Functioning in Adolescents and Young Adults with a Childhood History of Chronic Abdominal Pain Presentation.
CAUTION: The Spinal Modulation Axium™ Spinal Cord Stimulator System is an investigational device and is limited by United States law to investigational.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized commercial reproduction of this slide is prohibited Supplemental PowerPoint Slides Acupuncture.
Efficacy of Exercise in Reducing Depressive Symptoms.
Overview of Neurostimulation
Neuromodulation for Headache & Craniofacial Pain: 50 Consecutive Cases Paul Verrills MD, David Vivian MD, Bruce Mitchell MD and Adele Barnard PhD Metro.
Carolyn A Arnold Caulfield Pain Management & Research Centre, Alfred Health, Melbourne, Australia Outcome Assessment after Musculoskeletal Pain Rehabilitation.
Memantine in Clinical Practice – Results of an Observational Study Calabrese P., Essner U. and Förstl H. Dementia and Geriatric Cognitive Disorders 2007;
Inpatient program Mild TBI / Post-deployment stress Evaluations Treatment Multi- and Inter-disciplinary Post-deployment Rehabilitation & Evaluation Program.
Presented by Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmology Drug Products ODEV, CDER, FDA at the Arthritis Advisory.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
General Considerations for Analgesic Risk-Benefit Analyses Nathaniel Katz, MD, MS Analgesic Solutions, Natick, MA Tufts University School of Medicine,
Acute Spinal Cord Trauma Robert L Wears, MD, MS Practice Guidelines: A Pan-American Symposium Santiago de Chile 7 October 2003.
PROMIS ® : Advancing the Science of PRO measurement Common Data Elements NIH CDE Webinar September 8, 2015 Ashley Wilder Smith, PhD, MPH Chief, Outcomes.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
Development of Physical and Mental Health Summary Scores from PROMIS Global Items Ron D. Hays ( ) UCLA Department of Medicine
Introduction to the Patient-Reported Outcomes Measurement Information System (PROMIS) UCLA Center for East-West Medicine 2428 Santa Monica Blvd., Suite.
1 Presented by Eugene Laska, Ph.D. at the Arthritis Advisory Committee meeting 07/30/02.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
Surrogate Endpoints as Measures of Efficacy: Complexities & Limitations FDA Advisory Committee November 18, 2002 Michael D. Hughes, Ph.D. Professor of.
Long-Term Outcomes after Acute Stroke Treatment Larry B. Goldstein, M.D. Professor of Medicine (Neurology) Center for Cerebrovascular Disease Center for.
Patient-reported Outcome Functional Status Assessment (PRO FSA) Heart Failure Measure Testing Project 1.
Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Around-the-Clock, Controlled-Release Oxycodone Therapy.
Got outcome measures? What Clinicians & Investigators Want Lisa M. Shulman, M.D. The Eugenia Brin Professor in Parkinson’s Disease and Movement Disorders.
+ Interdisciplinary Care in Pediatric Chronic Pain Emily Law, PhD Assistant Professor Department of Anesthesiology & Pain Medicine University of Washington.
Disability After Traumatic Brain Injury among Hispanic Children
CIPN: Considerations for Drug Development
Some epidemiological principles and methods
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
Fibromyalgia Impact Questionnaire McGill Pain Questionnaire
Non-lab observables The Observables project is supposed to develop a/the model for non-lab observables during 2012 Non-lab → unlimited scope Need for.
Analysis of a New Method for Studying Placebo Effects
Methodological challenges of studying CIPN during chemotherapy
CLINICAL PROTOCOL DEVELOPMENT
Pain Management.
Quality of Life Assessment
Synergetic effect of Intrathecal Baclofen and Deep Brain Stimulation in treating Dystonia 51 Authors Yasser Awaad, MD, MSc, FAAN, FAAP 1&2 & Tamer Rizk,
Evaluating the Immediate Effectiveness of an Outpatient Pain Management Programme on Pain Related Interference: Outcomes from a Discrete Island-Based Chronic.
Overview of PainTracker Progress to-date at UW Medicine
PAIN ASSESSMENT Pain is internal, subjective experience.
The Relationship Between Mental and Physical Health
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
Treatment of Clients Experiencing Pain Disorders
INTERNATIONAL SOCIETY FOR THERAPEUTIC ULTRASOUND –TEL AVIV, ISRAEL-MARCH 14-16, 2016 Musculoskeletal Clinical Applications of Intense Therapy Ultrasound.
Treatment of Clients Experiencing Pain Disorders
Improvement in Lumbar Radiculopathy
Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment
Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee  Najib.
Translation Pathway for Coronary Stent Development- Clinical Endpoints
IMMPACT-XXI July 26-27, 2018 Washington, DC
How to Measure Quality of Life
Patient-reported Outcome Measures
Gregory Levin, FDA/CDER/OTS/OB/DBIII
Clinical Assessment Tools
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

Outcomes in SCS Trials Ali Rezai MD

Clinical Trial Outcomes What are outcomes? What are the different types of outcomes? How are they measured? What are some of the challenges? Outcomes in SCS trials

What are “Outcomes”? Outcomes are variables or data points measured in trials to determine the impact of an intervention on a certain measure Safety, feasibility, tolerability, efficacy Different audiences may be interested in different measures Patients / families, healthcare providers, regulators, payors

Different Types of Outcomes Patient centric (subjective and objective) Survival, subjective pain scores, quality of life, satisfaction Surrogate – includes biomarkers 6 minute walk distance – transplant or mortality Cholesterol – cardiovascular mortality Composite Major adverse cardiac events (MACE); pain score + opioid dose reduction

How are Outcomes Measured? Patient reported Pain NRS scores, subjective measures Family reported Pediatrics, Patients with cognitive deficits Provider reported Physical measures, objective measures

Challenges of Outcomes Different audiences disagree about the relevance / value of particular ones Questions about validity of selected measures Impact of placebo / sham on measuring outcomes Generalizability to non-study conditions or populations Variability and reliability of subjective measures (e.g. pain) Uni-dimensional measures used for multi-dimensional constructs

Efficacy Outcomes in Chronic Pain* 11-point (0-10) numerical rating scale of pain intensity Usage of rescue analgesics Categorical rating of pain intensity (none, mild, moderate, severe) when necessary Physical functioning (either one of two measures) – Multidimensional Pain Inventory Interference Scale or Brief Pain Inventory Interference Items Emotional functioning (at least one of two measures) – Beck Depression Inventory or Profile of Mood States Participant ratings of global improvement and satisfaction with treatment Patient Global Impression of Change Symptoms and adverse events – Passive capture of spontaneously reported adverse events and symptoms and use of open-ended prompts Participant disposition – Detailed information regarding participant recruitment and progress through the trial, including all information specified in the CONSORT guidelines *Dworkin, Pain 113 (2005) 9–19

Relevant Outcomes in SCS Trials

Safety Procedure Related Bleeding, infection, wound Neurologic injury Neurological Sensory and motor deficits Device Related Infection, erosion, failed hardware, disconnection Stimulation Related Other New pain syndromes Worsening of pain Poor hardware placement

Feasibility Impact considerations of treatment on patient and support system Technical / procedural

Efficacy – Pain Intensity VAS NRS Faces Dose of concomitant opioid or other analgesics Responder analysis

Efficacy – Pain Quality McGill Pain Questionnaire (Short Form) Pain Detect Questionnaire Brief Pain Inventory

Efficacy – Quality of Life / Functional Patient Reported Outcomes Measurement Information System (PROMIS-29) Oswestry disability index (ODI) SF-36 EQ5D QALY Days out of work

Efficacy – Satisfaction with Treatment Patient Satisfaction Provider Satisfaction

Topics for Discussion Validity / Reliability Placebo / sham effect Generalizability Duration of measurement: <3 months, 3, 6, 12, >12 months When to include a responder analysis Objective measurements for pain including surrogates Biomarkers, imaging, EEG, function, others… Composites for pain, multi-dimensional